Greg Pyszczymuka - 30 Jun 2023 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role
Chief Commerical Officer
Signature
/s/ Mark Oki as attorney-in-fact for Greg Pyszczymuka
Issuer symbol
AYTU
Transactions as of
30 Jun 2023
Net transactions value
$0
Form type
4
Filing time
06 Jul 2023, 15:26:53 UTC
Previous filing
20 Jun 2023
Next filing
15 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AYTU Common Shares Options Exercise +208 +0.95% 22,143 30 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AYTU Restricted Stock Units Options Exercise $0 -208 -12% $0.000000 1,459 30 Jun 2023 Common Shares 208 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.